Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions - Wikidata - wikimedia - TriplyDB

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

http://www.wikidata.org/entity/Q34691742

about

Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function Arachidonic acid monooxygenase: Genetic and biochemical approaches to physiological/pathophysiological relevance Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy.Epoxyeicosatrienoic acids and cardioprotection: the road to translation The role of epoxyeicosatrienoic acids in the cardiovascular system Epoxyeicosatrienoic acids, hypertension, and kidney injury Cytochrome P450 eicosanoids and cerebral vascular function Epoxides and soluble epoxide hydrolase in cardiovascular physiology Epoxyeicosatrienoic Acid Analog Decreases Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition.Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition.Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury.Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity.A novel vascular EET synthase: role of CYP2C7 Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension.Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat.The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt.Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.Microsomal cytochrome P450 as a target for drug discovery and repurposing.Agonists of epoxyeicosatrienoic acids reduce infarct size and ameliorate cardiac dysfunction via activation of HO-1 and Wnt1 canonical pathway.Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications.Anti-inflammatory ω-3 endocannabinoid epoxides.Orally Active Epoxyeicosatrienoic Acid Analogs.

P2860

Q26849271-647516E8-8C97-481B-A620-AFADC76A9F56 Q27024958-0BB2078C-EEA4-43B0-832B-F722C20B2E7E Q27334040-ECCEA9DB-4DE4-4E89-B747-F412835E2CD7 Q28241262-EA899E23-877C-4220-B822-98DFED9D1EE1 Q28256560-90E7DB96-92D9-4EE0-B9D1-C1EF2B56363D Q28387823-A9EA26E7-936E-411F-A7BE-1DDA7EBB6BEC Q28396302-292C0B19-C1AB-42E7-9CFD-29CDBD849094 Q28396313-353852AF-433F-4982-B81F-6B0D7994A803 Q33854978-AD1C551D-226B-43A0-BFAC-B291AD846F90 Q33904690-11FDDA18-9566-4134-993E-57D36F26D91F Q34205948-558390CE-4C74-4CFB-AC4E-6BE89E00862B Q34229608-918FF526-1777-4F91-8050-EDB13FA43D6A Q34238703-1FCEACC3-1035-46F6-9679-6C8B0919A85D Q35601565-004639E3-CE9D-4279-ACB0-54B54B60ECE8 Q35608633-BB415E0D-B66A-437B-BE8E-59F036159EA4 Q37022931-2511A90A-1A0E-43DB-B1DB-D4BDBB68F53F Q37414424-6E37FC73-E0D1-4075-B0C5-2521AB8BABFA Q37583586-DFA03598-762A-4E81-8A17-F3F412D5D7E0 Q37960812-4182765D-4109-4F22-AE38-2825B982899B Q39000644-0377EEDF-6E91-4234-85CA-B024F4065101 Q41362375-547686FC-A694-4C84-A1E2-1B30C9A211F9 Q41648482-28B9CDD1-5EE8-4A6A-BA24-F1720EFD4EAD Q42070301-D6852B2F-FD5B-4E4B-9D96-09230C790984 Q47948005-D362A280-E09D-4A73-8D32-E589B6B4A600 Q49929536-E1D363DA-24DA-4DD6-83F3-E104EE321271

P2860

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

http://www.wikidata.org/entity/Q34691742

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@ast

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@en

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@nl

type

label

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@ast

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@en

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@nl

prefLabel

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@ast

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@en

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@nl

P1433

Q34691742-31C6ABAC-314A-4183-8013-6C77FD3C4E9C

P1476

Q34691742-DB91AA4A-2147-4A0E-A9FD-B271C43A5705

P2093

Q34691742-1B758834-43C3-4854-AD67-1533C4888B12

Q34691742-29DC04BE-BD7C-4C62-B03B-36E7121FCAD4

Q34691742-419E68B5-395D-48D0-B916-434BDD6302DB

Q34691742-8BEB45EC-9C86-4DD9-8691-4ACE97221A6C

Q34691742-9D5BCF73-2267-44B0-B31F-76BA29E27C83

Q34691742-A67B8BDF-42BF-41AF-B0DD-70F1F8448612

Q34691742-D381EB02-0076-49A4-B6AC-7ED2ACFD1F21

Q34691742-D8998421-B5CE-4036-BF75-0CC4DC7DB71D

Q34691742-D96BEF20-8594-4C55-8CB8-D208100F72D4

P2860

Q34691742-0D182EB5-C25B-424B-94CF-632D33BF9E4C

Q34691742-0E63664B-C5D1-480A-8581-1E4986BE76F5

Q34691742-0F5D02A4-664B-45AC-BCD3-07E8E5480364

Q34691742-10D04706-BB16-473F-88AC-9AB1FAD7BFB3

Q34691742-22EF27A5-D523-4A88-9030-53431E815286

Q34691742-482E3E78-697D-41FE-9272-DB652184FE4D

Q34691742-52648B96-B7C3-43A2-AC99-ABB574BDDAD2

Q34691742-53A46381-50B5-4FFF-BF49-C65EA06B7AB1

Q34691742-60024FEF-1B20-4D86-BD12-4270747266A9

Q34691742-765502DA-F38E-4DF4-BF8B-0D2B0B2BED80

P304

Q34691742-6F681B1E-5B62-42B6-A579-0A1E93C9621E

P31

Q34691742-9042B2E8-A926-4D2D-B8B3-07C8B0A762B4

P356

Q34691742-F7FEF306-CA77-487A-986D-246ABA6AE3AA

P478

Q34691742-E2C940E3-1470-42C7-BD96-57BF6CD9983F

P50

Q34691742-387B585F-CE99-4A96-B136-BB9E15592414

Q34691742-FF87CB89-B18B-4F99-8540-F3818919D3A2

P577

Q34691742-E4A45AF0-E565-4D77-9A30-E87711358B57

P5875

Q34691742-B9FD7015-262E-4FF2-99AE-22A27723CA05

P698

Q34691742-FBBBD60B-A3BB-4150-9DA8-9016EA7AA7F0

P932

Q34691742-AA6E272A-A51A-4D9A-9DC5-1306AFE7550B

P356

FPHYS.2010.00157

P1433

Frontiers in Physiology

P1476

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

@en

P2093

Ahmed Elmarakby

http://www.w3.org/2001/XMLSchema#string

Bhavani Sangras

http://www.w3.org/2001/XMLSchema#string

D Sudarshan Reddy

http://www.w3.org/2001/XMLSchema#string

Jorge H Capdevila

http://www.w3.org/2001/XMLSchema#string

Kasem Nithipatikom

http://www.w3.org/2001/XMLSchema#string

Shouzou Wei

http://www.w3.org/2001/XMLSchema#string

Siddam Anjaiah

http://www.w3.org/2001/XMLSchema#string

Venugopal Raju Tuniki

http://www.w3.org/2001/XMLSchema#string

Vijaya L Manthati

http://www.w3.org/2001/XMLSchema#string

P2860

Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

Cytochrome P450 2C is an EDHF synthase in coronary arteries

Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice

Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury

Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors

Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

Epoxygenase pathways of arachidonic acid metabolism.

Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.

An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension

P304

157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHYS.2010.00157

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50596909

http://www.w3.org/2001/XMLSchema#string

P698

21423396

http://www.w3.org/2001/XMLSchema#string

P932

3059925

http://www.w3.org/2001/XMLSchema#string